RYTM Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of 40.12%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 44.54%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 43.76%. Given that Rhythm Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Rhythm Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 15.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 25.61x versus 5.57x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -10220.14%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Cytokinetics's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 44.54%. On the other hand Cytokinetics has an analysts' consensus of $73.45 which suggests that it could grow by 139.95%. Given that Cytokinetics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Cytokinetics is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are larger than Cytokinetics quarterly revenues of $1.6M. Rhythm Pharmaceuticals's net income of -$49.5M is higher than Cytokinetics's net income of -$161.4M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 25.61x versus 184.58x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -50.09%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Geron's return on equity of -46.58%.

Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 44.54%. On the other hand Geron has an analysts' consensus of $3.69 which suggests that it could grow by 207.29%. Given that Geron has higher upside potential than Rhythm Pharmaceuticals, analysts believe Geron is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Geron quarterly revenues of $39.6M. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Geron's net income of -$19.8M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 25.61x versus 6.83x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of 26.7%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Rhythm Pharmaceuticals has a consensus price target of $82.08, signalling upside risk potential of 44.54%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $793.05 which suggests that it could grow by 38.12%. Given that Rhythm Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe Rhythm Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.362, which suggesting that the stock is 136.233% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 25.61x versus 4.65x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.